(Q41630478)

5 October 2017

1 reference

title

Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management (English)

1 reference

5 October 2017

1 reference

S H Hohnloser

1

1 reference

5 October 2017

language of work or name

English

0 references

publication date

1 October 1997

1 reference

American Journal of Cardiology

5 October 2017

published in

1 reference

5 October 2017

volume

80

1 reference

5 October 2017

issue

8A

1 reference

5 October 2017

page(s)

82G-89G

1 reference

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

5 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). The CASCADE Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Aggravation of arrhythmia induced with antiarrhythmic drugs during electrophysiologic testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Proarrhythmic effects of antiarrhythmic drugs in patients with malignant ventricular arrhythmias evaluated by electrophysiologic testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Application of a frequency definition of ventricular proarrhythmia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Aggravation of ventricular arrhythmia. A drug-induced complication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Proarrhythmic responses during electrophysiologic testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Electrophysiologic substrate of torsade de pointes: dispersion of repolarization or early afterdepolarizations?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Mechanisms of arrhythmogenic delayed and early afterdepolarizations in ferret ventricular muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle length.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Barium-induced nondriven action potentials as a model of triggered potentials from early afterdepolarizations: significance of slow channel activity and differing effects of quinidine and amiodarone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

QTU prolongation and polymorphic ventricular tachyarrhythmias due to bradycardia-dependent early afterdepolarizations. Afterdepolarizations and ventricular arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Distribution of M cells in the canine ventricle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Characteristics and possible mechanism of ventricular arrhythmia dependent on the dispersion of action potential durations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome. Tridimensional mapping of activation and recovery patterns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Heterogeneity within the ventricular wall. Electrophysiology and pharmacology of epicardial, endocardial, and M cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

A subpopulation of cells with unique electrophysiological properties in the deep subepicardium of the canine ventricle. The M cell

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Modulation of potassium channels by antiarrhythmic and antihypertensive drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Electrophysiologic effects of the levo- and dextrorotatory isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Clinical safety profile of sotalol in patients with arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Sex difference in risk of torsade de pointes with d,l-sotalol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Torsades de pointes and proarrhythmia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Electrocardiographic quantitation of ventricular repolarization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Acute and chronic antiarrhythmic efficacy of d-sotalol in patients with sustained ventricular tachyarrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Effectiveness of amiodarone on ventricular arrhythmias during and after acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Beneficial effects of low dose amiodarone in patients with congestive cardiac failure: a placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Post-myocardial infarction mortality in patients with ventricular premature depolarizations. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Suppression of time-dependent outward current in guinea pig ventricular myocytes. Actions of quinidine and amiodarone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Channel specificity in antiarrhythmic drug action. Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Amiodarone blocks inactivated cardiac sodium channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Frequency-dependent effects of amiodarone on atrioventricular nodal function and slow-channel action potentials: evidence for calcium channel-blocking activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

The adrenergic antagonism of amiodarone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Bradycardia-dependent triggered activity: relevance to drug-induced multiform ventricular tachycardia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Frequency-dependent electrophysiologic effects of amiodarone in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Effects of amiodarone, sematilide, and sotalol on QT dispersion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Effects of amiodarone on the circadian rhythm and power spectral changes of heart rate and QT interval: significance for the control of sudden cardiac death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Controlling Cardiac Arrhythmias by Lengthening Repolarization: Rationale from Experimental Findings and Clinical Considerationsa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Magnesium therapy for torsades de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Treatment of torsade de pointes with magnesium sulfate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Efficacy of magnesium sulfate in the treatment of torsade de pointes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Magnesium suppression of early afterdepolarizations and ventricular tachyarrhythmias induced by cesium in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

Quinidine-induced action potential prolongation, early afterdepolarizations, and triggered activity in canine Purkinje fibers. Effects of stimulation rate, potassium, and magnesium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900717-0

10.1016/S0002-9149(97)00717-0

7 January 2021

Identifiers

DOI

1 reference

5 October 2017

1 reference